HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effect of parathyroid hormone administration in a patient with severe hypoparathyroidism caused by gain-of-function mutation of calcium-sensing receptor.

Abstract
Hypoparathyroidism caused by gain-of-function mutations of the calcium-sensing receptor (CaR) in the transmembrane domain is usually severe and difficult to manage. A patient with severe hypoparathyroidism, caused by CaR activating mutation F821L, was treated for 3 days (Day 1 to Day 3) with synthetic human parathyroid hormone 1-34 (teriparatide, PTH). An Ellsworth-Howard test of the patient revealed normal responses of urine phosphate and cyclic AMP excretion, indicating that the patient's renal tubules normally responded to extrinsic PTH. On Day 1 to Day 3, 0.9 microg/kg/day of PTH was administered subcutaneously twice daily at 0800 and 2000. On Day 1, the serum calcium level that was 1.8 mmol/l before PTH administration increased to 2.1 mmol/l at 1200, and gradually decreased to 1.8 mmol/l at 2000. On Days 2 and 3, the maximum calcium levels were 2.5 and 2.4 mmol/l, respectively, at 1200. At 2000, they returned to or below basal levels at 0800. On Day 4 without PTH administration, the calcium levels were maintained at the basal levels at Day 0. The urine calcium/creatinine (Ca/Cr) ratio that was high (>0.4) before PTH injection decreased after PTH administration (0.4>). Changes in the ionized calcium levels were almost parallel with the total calcium levels. The serum inorganic phosphate (IP) level decreased to 2.4 mmol/l at 1000, but gradually increased before the second PTH injection to the level at 0800 on Day 1. The minimum IP level on Days 2 and 3 was 2.1 mmol/l and 2.0 mmol/l, respectively. In contrast to the remarkable changes in the serum calcium level by PTH treatment, the serum magnesium levels showed few changes. These results indicate that PTH therapy could be effective in correcting serum and urine calcium and the phosphate levels in hypoparathyroidism caused by activating mutation of CaR.
AuthorsMasaaki Shiohara, Riyo Shiozawa, Kenji Kurata, Hiroki Matsuura, Fumi Arai, Toshiyuki Yasuda, Kenichi Koike
JournalEndocrine journal (Endocr J) Vol. 53 Issue 6 Pg. 797-802 (Dec 2006) ISSN: 0918-8959 [Print] Japan
PMID16983178 (Publication Type: Case Reports, Journal Article)
Chemical References
  • PTH protein, human
  • Parathyroid Hormone
  • Receptors, Calcium-Sensing
  • Teriparatide
  • Phosphorus
  • Creatinine
  • Cyclic AMP
  • Magnesium
  • Calcium
Topics
  • Calcium (blood)
  • Child
  • Creatinine (blood)
  • Cyclic AMP (urine)
  • Humans
  • Hypoparathyroidism (blood, drug therapy, genetics, urine)
  • Magnesium (blood)
  • Male
  • Mutation
  • Parathyroid Hormone (blood)
  • Phosphorus (urine)
  • Receptors, Calcium-Sensing (genetics)
  • Teriparatide (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: